CU20120035A7 - Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 - Google Patents

Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3

Info

Publication number
CU20120035A7
CU20120035A7 CUP2012000035A CU20120035A CU20120035A7 CU 20120035 A7 CU20120035 A7 CU 20120035A7 CU P2012000035 A CUP2012000035 A CU P2012000035A CU 20120035 A CU20120035 A CU 20120035A CU 20120035 A7 CU20120035 A7 CU 20120035A7
Authority
CU
Cuba
Prior art keywords
antibodies
dual specificity
glicolil
gangliosids
acetil
Prior art date
Application number
CUP2012000035A
Other languages
English (en)
Other versions
CU24120B1 (es
Inventor
Frías Ernesto Moreno
Dorantes Gertrudis Rojas
Pazos Ana Victoria Casadesus
Original Assignee
Ct De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48039960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20120035(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct De Inmunología Molecular filed Critical Ct De Inmunología Molecular
Priority to CU20120035A priority Critical patent/CU24120B1/es
Priority to EP13713074.6A priority patent/EP2821417A2/en
Priority to PCT/CU2013/000001 priority patent/WO2013127373A2/es
Priority to CA2865050A priority patent/CA2865050A1/en
Priority to KR1020147024181A priority patent/KR20140126349A/ko
Priority to EA201491618A priority patent/EA201491618A1/ru
Priority to MX2014010456A priority patent/MX2014010456A/es
Priority to US14/379,628 priority patent/US9527920B2/en
Priority to PE2014001340A priority patent/PE20142277A1/es
Priority to CN201380011913.7A priority patent/CN104136463B/zh
Priority to AU2013225453A priority patent/AU2013225453A1/en
Priority to SG11201405151YA priority patent/SG11201405151YA/en
Priority to JP2014559092A priority patent/JP5933044B2/ja
Priority to TW102106707A priority patent/TW201348259A/zh
Priority to ARP130100653A priority patent/AR090207A1/es
Publication of CU20120035A7 publication Critical patent/CU20120035A7/es
Priority to TNP2014000330A priority patent/TN2014000330A1/fr
Priority to CL2014002236A priority patent/CL2014002236A1/es
Priority to CO14187637A priority patent/CO7051011A2/es
Priority to PH12014501950A priority patent/PH12014501950A1/en
Priority to IL234394A priority patent/IL234394A0/en
Priority to ZA2014/07043A priority patent/ZA201407043B/en
Priority to HK14112117.7A priority patent/HK1198654A1/xx
Publication of CU24120B1 publication Critical patent/CU24120B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención se relaciona con nuevos anticuerpos monoclonales y fragmentos de estos anticuerpos, con especificidad dual y alta afinidad por los gangliósidos N-acetil GM3 y N-glicolil GM3, y que no reconocen otros gangliósidos. En otro aspecto, la presente invención se relaciona con el uso de estos anticuerpos y sus fragmentos en la terapia de tumores que tienen una expresión significativa de cualquiera de los dos antígenos reconocidos por estos anticuerpos, o una expresión mixta de ambos antígenos. Así como al uso de estos anticuerpos en el diagnóstico de tumores que expresen al menos uno de los antígenos.
CU20120035A 2012-03-01 2012-03-01 Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 CU24120B1 (es)

Priority Applications (22)

Application Number Priority Date Filing Date Title
CU20120035A CU24120B1 (es) 2012-03-01 2012-03-01 Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
PCT/CU2013/000001 WO2013127373A2 (es) 2012-03-01 2013-02-21 Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
AU2013225453A AU2013225453A1 (en) 2012-03-01 2013-02-21 Recombinant antibodies having dual specificity for gangliosides and use thereof
JP2014559092A JP5933044B2 (ja) 2012-03-01 2013-02-21 ガングリオシドに対する二重特異性を有する組換え抗体及びこれらの使用
CA2865050A CA2865050A1 (en) 2012-03-01 2013-02-21 Recombinant antibodies having dual specificity for gangliosides and use thereof
KR1020147024181A KR20140126349A (ko) 2012-03-01 2013-02-21 강글리오시드에 대한 이중 특이성을 갖는 재조합 항체 및 그 용도
EA201491618A EA201491618A1 (ru) 2012-03-01 2013-02-21 Рекомбинантные антитела с двойной специфичностью к ганглиозидам и их применение
MX2014010456A MX2014010456A (es) 2012-03-01 2013-02-21 Anticuerpos recombinantes con especificidad dual por gangliosidos y su uso.
US14/379,628 US9527920B2 (en) 2012-03-01 2013-02-21 Recombinant antibodies having dual specificity for gangliosides and use thereof
PE2014001340A PE20142277A1 (es) 2012-03-01 2013-02-21 Anticuerpos recombinantes con especificidad dual por gangliosidos y su uso
CN201380011913.7A CN104136463B (zh) 2012-03-01 2013-02-21 具有对于神经节苷脂的双重特异性的重组抗体以及其用途
EP13713074.6A EP2821417A2 (en) 2012-03-01 2013-02-21 Recombinant antibodies having dual specificity for gangliosides and use thereof
SG11201405151YA SG11201405151YA (en) 2012-03-01 2013-02-21 Recombinant antibodies having dual specificity for gangliosides and use thereof
TW102106707A TW201348259A (zh) 2012-03-01 2013-02-26 對神經節苷脂類具雙重專一性之重組抗體及其用途
ARP130100653A AR090207A1 (es) 2012-03-01 2013-02-28 Anticuerpos recombinantes con especificidad dual por gangliosidos y su uso
TNP2014000330A TN2014000330A1 (en) 2012-03-01 2014-07-31 Recombinant antibodies having dual specificity for gangliosides and use thereof
CL2014002236A CL2014002236A1 (es) 2012-03-01 2014-08-22 Anticuerpos recombinantes con especificidad dual por gangliósidos n-acetil gm3 y n-glicolil gm3 y su uso.
CO14187637A CO7051011A2 (es) 2012-03-01 2014-08-27 Anticuerpos recombinantes con especificidad dual por gangliósidos y su uso
PH12014501950A PH12014501950A1 (en) 2012-03-01 2014-08-29 Recombinant antibodies having dual specificity for gangliosides and use thereof
IL234394A IL234394A0 (en) 2012-03-01 2014-08-31 Recombinant antibodies with dual specificity for gangliosides and their use
ZA2014/07043A ZA201407043B (en) 2012-03-01 2014-09-29 Recombinant antibodies having dual specificity for gangliosides and use thereof
HK14112117.7A HK1198654A1 (en) 2012-03-01 2014-12-02 Recombinant antibodies having dual specificity for gangliosides and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20120035A CU24120B1 (es) 2012-03-01 2012-03-01 Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3

Publications (2)

Publication Number Publication Date
CU20120035A7 true CU20120035A7 (es) 2013-10-29
CU24120B1 CU24120B1 (es) 2015-08-27

Family

ID=48039960

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20120035A CU24120B1 (es) 2012-03-01 2012-03-01 Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3

Country Status (22)

Country Link
US (1) US9527920B2 (es)
EP (1) EP2821417A2 (es)
JP (1) JP5933044B2 (es)
KR (1) KR20140126349A (es)
CN (1) CN104136463B (es)
AR (1) AR090207A1 (es)
AU (1) AU2013225453A1 (es)
CA (1) CA2865050A1 (es)
CL (1) CL2014002236A1 (es)
CO (1) CO7051011A2 (es)
CU (1) CU24120B1 (es)
EA (1) EA201491618A1 (es)
HK (1) HK1198654A1 (es)
IL (1) IL234394A0 (es)
MX (1) MX2014010456A (es)
PE (1) PE20142277A1 (es)
PH (1) PH12014501950A1 (es)
SG (1) SG11201405151YA (es)
TN (1) TN2014000330A1 (es)
TW (1) TW201348259A (es)
WO (1) WO2013127373A2 (es)
ZA (1) ZA201407043B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24120B1 (es) * 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
EP3277713A1 (en) * 2015-03-31 2018-02-07 VHsquared Limited Polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4107154A1 (de) 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
CU22731A1 (es) 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
CU24120B1 (es) * 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3

Also Published As

Publication number Publication date
WO2013127373A3 (es) 2013-10-31
AU2013225453A1 (en) 2014-09-25
AR090207A1 (es) 2014-10-29
CU24120B1 (es) 2015-08-27
CN104136463A (zh) 2014-11-05
JP5933044B2 (ja) 2016-06-08
EP2821417A2 (en) 2015-01-07
CL2014002236A1 (es) 2014-12-05
ZA201407043B (en) 2015-12-23
WO2013127373A2 (es) 2013-09-06
US9527920B2 (en) 2016-12-27
CA2865050A1 (en) 2013-09-06
MX2014010456A (es) 2014-10-13
IL234394A0 (en) 2014-10-30
PE20142277A1 (es) 2015-01-15
SG11201405151YA (en) 2014-10-30
US20150093385A1 (en) 2015-04-02
TW201348259A (zh) 2013-12-01
KR20140126349A (ko) 2014-10-30
JP2015516367A (ja) 2015-06-11
TN2014000330A1 (en) 2015-12-21
CO7051011A2 (es) 2014-09-10
PH12014501950A1 (en) 2014-11-24
EA201491618A1 (ru) 2014-12-30
CN104136463B (zh) 2016-08-24
EP2821417A9 (en) 2015-04-01
HK1198654A1 (en) 2015-05-22

Similar Documents

Publication Publication Date Title
CU20110009A7 (es) Anticuerpos neutralizantes de citomegalovirus humano
UY35013A (es) Composiciones farmacéuticas que contienen un antagonista de il-4r y sus usos
AR089978A1 (es) Translocaciones de la r-espondina y sus metodos de uso, metodo de tratamiento, antagonistas
UY35399A (es) Conjugados de fármacos con anticuerpos
MX348637B (es) Anticuerpos y composiciones anti-her3.
BR112015007184A2 (pt) combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
BR112014026755B8 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
CO6420350A2 (es) Proteinas de union especificas y sus usos
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
PH12015500480B1 (en) Antibody formulations and uses thereof
BR112014018964A8 (pt) Anticorpo anti-vegf e uso de um anticorpo anti-vegf
EA201690992A1 (ru) Антитела, специфичные к fcrn
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
CU20120035A7 (es) Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
BR112015027249A2 (pt) método de diagnóstico de câncer
BR112015028997A2 (pt) biomarcadores de expressão gênica e seu uso para a aplicação diagnóstica e prognóstica em pacientes potencialmente com necessidade de tratamento de inibidor de hdac
BR112016020043A2 (pt) composições e métodos para a identificação de malignidades de linfócitos b responsivas à terapia de depleção de linfócitos b
BR112015031585A2 (pt) composição farmacêutica
CU20110245A7 (es) Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
TH158323A (th) รีคอมบิแนนท์แอนติบอดีที่มีสองความจำเพาะสำหรับแกงกลิโอไซด์ และการใช้ของพวกมัน
ITFI20120164A1 (it) Nuovi peptidi glicosilati.

Legal Events

Date Code Title Description
FG Grant of patent